Tirzepatide vs Dulaglutide: Long-Term Cost-Effectiveness Comparison
Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
Quick Facts
What This Study Found
Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
Key Numbers
Tirzepatide 5 mg vs. dulaglutide 0.75 mg, both once weekly. 50-year time horizon. Based on SURPASS J-mono trial results.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dul
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(3), 431-445 (2025)
- Authors:
- Aranishi, Toshihiko, Igarashi, Ataru, Hara, Kazuo, Osumili, Beatrice, Cai, Zhihong, Mizogaki, Aska, Sato, Manaka, Takeuchi, Masakazu, Minghetti, Alice, Hunt, Barnaby, Kadowaki, Takashi
- Database ID:
- RPEP-09965
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09965APA
Aranishi, Toshihiko; Igarashi, Ataru; Hara, Kazuo; Osumili, Beatrice; Cai, Zhihong; Mizogaki, Aska; Sato, Manaka; Takeuchi, Masakazu; Minghetti, Alice; Hunt, Barnaby; Kadowaki, Takashi. (2025). The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(3), 431-445. https://doi.org/10.1007/s13300-024-01675-7
MLA
Aranishi, Toshihiko, et al. "The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.." Diabetes therapy : research, 2025. https://doi.org/10.1007/s13300-024-01675-7
RethinkPeptides
RethinkPeptides Research Database. "The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus ..." RPEP-09965. Retrieved from https://rethinkpeptides.com/research/aranishi-2025-the-longterm-costeffectiveness-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.